De Novo device
Pill Sense System
Enterasense , Ltd. · Blood Detection Capsule (QUD, Class II) · First FDA decision Feb 24, 2023, newest Feb 24, 2023Gastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
2
Naming "Pill Sense"
MAUDE reports
0
Brand "Pill Sense", since 2015
PubMed studies
0
Mentioning "Pill Sense"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Pill Sense System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Pill Sense SystemNew device typeDe Novo
DEN220065 · Decided Feb 24, 2023 · 148 days after receipt
Device type: Blood Detection Capsule (QUD) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Pill Sense", any status and sponsor, newest update first.
- Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted TherapiesActive, not recruiting
University of VirginiaAcademic, hospital or other
NCT05370469 · 30 participants · Start Aug 25, 2022 · Primary completion Jun 14, 2024
Device: RX Cap; Fitbit Sense · For: Lung Cancer; EGFR Gene Mutation; EGFR and 6 more
Sites: Charlottesville, Virginia
Lithuanian University of Health SciencesAcademic, hospital or other
NCT02926014 · 100 participants · Start Oct 2014 · Primary completion May 2016
Device: Videolaryngoscopy · For: Lingual Tonsil Hypertrophy; Dysphagia
Sites: Kaunas, Lithuania
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Pill Sense", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QUD
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Pill Sense"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.